27.5亿美元！礼来×英矽智能达成合作，开发口服版GLP-1类药物

Core Viewpoint - Eli Lilly and Insilico Medicine have deepened their collaboration with a drug development partnership worth up to $2.75 billion, including an upfront payment of $115 million, which has triggered antitrust scrutiny from the FTC and rumors of a potential acquisition of Insilico by Eli Lilly [2]. Group 1: Collaboration Details - The partnership aims to expand Eli Lilly's use of Insilico's AI drug development engine, Pharma.AI, to develop new therapies [2]. - Eli Lilly has obtained global exclusive licensing rights for a preclinical oral GLP-1 weekly formulation developed by Insilico [2]. Group 2: Market Context - In the GLP-1 sector, Eli Lilly has surpassed Novo Nordisk with its dual receptor agonist Tirzepatide compared to Semaglutide [3]. - Oral formulations are considered to have higher compliance rates, with Eli Lilly's small molecule GLP-1 receptor agonist Orforglipron having submitted applications for obesity and type 2 diabetes treatment in the US and China [3]. - The candidate drug from Insilico aims to improve dosing frequency to once a week, compared to daily dosing for existing oral GLP-1 medications [3].